Drug Profile
IFX 002
Alternative Names: IFX-002; IFX-2Latest Information Update: 22 Jun 2022
Price :
$50
*
At a glance
- Originator InflaRx
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
Most Recent Events
- 22 Jun 2022 IFX 002 is still in preclinical trials for Inflammation in Germany (Parenteral, Injection) (InflaRx pipeline, June 2022)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Inflammation in Germany (Parenteral, Injection)
- 28 Apr 2020 Preclinical development is still ongoing for Inflammation in Germany (InflaRx pipeline, April 2020)